MDG_LOGO_2016_GRAY_RGB.jpg
Medigene will Present at ASGCT 2024 and Host R&D Event
02 oct. 2024 09h00 HE | Medigene AG
Planegg/Martinsried, October 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Expands Protection of its KRAS Library with Filing of New Patent Application Supporting MDG2021
25 sept. 2024 03h00 HE | Medigene AG
Planegg/Martinsried, September 25, 2024 – Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Host Virtual R&D Event on Medigene’s Optimal 3S TCRs for TCR-Guided Precision Immunotherapies
16 sept. 2024 08h30 HE | Medigene AG
Planegg/Martinsried, September 16, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024
14 sept. 2024 07h30 HE | Medigene AG
Planegg/Martinsried, September 14, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene Announces U.S. FDA Clearance of IND Application for MDG1015, a First-in-Class, Third Generation T Cell Receptor Engineered T Cell (TCR-T) Therapy for Multiple Solid Tumor Indications
05 sept. 2024 08h00 HE | Medigene AG
Planegg/Martinsried, September 5, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Secures Two Additional Patents for Technologies in Its End-to-End Platform
29 août 2024 05h00 HE | Medigene AG
Planegg/Martinsried, August 29, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at Upcoming Investor Conferences
28 août 2024 05h00 HE | Medigene AG
Planegg/Martinsried, August 28, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG implements announced 2:1 share capital reduction and consolidation of the shares effective August 29, 2024
26 août 2024 05h00 HE | Medigene AG
Number of shares issued decreases from 29,475,189 to 14,737,594 due consolidation of the shares at a ratio of 2:1Consolidation of shares to take place on August 29, 2024 Planegg/Martinsried,...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update
14 août 2024 01h30 HE | Medigene AG
Significant corporate and scientific progress in the first half of 2024Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024New additions to...
MDG_LOGO_2016_GRAY_RGB.jpg
Medigene to Present at ESMO Congress 2024
23 juil. 2024 05h15 HE | Medigene AG
Planegg/Martinsried, July 23, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...